To Investigate the regional variability In arterial and venous endothellal prostacyclin (PGIj) biosynthesis, we obtained 1-cm segments of carotid arteries, external jugular veins, femoral arteries and veins, lilac arteries and veins, Inferior venae cavae (IVC), and aortas from 17 dogs. Vessel lumlnal PGI 2 production was measured In the basal state by radlolmmunoassay of 6-keto-prostaglandln F 1o (6-keto-PGF 1a ). A total of 90 arterial specimens (57, 19, and 14 segments, respectively, of femoral/carotid arteries, lilac arteries, and aorta) and 41 venous specimens (15,10, and 16 segments, respectively, of femoral/jugular veins, lilac veins, and IVC) were analyzed. Overall, arterial endothellal 6-keto-PGF 1a was higher than venous (8.1 ±0.5 ng/ml vs. 4.9±0.7 ng/ml, p<0.0004); 6-keto-PGF 1a levels were greater In the arteries than In their corresponding veins [femoral/carotid arteries (6.3±0.4 ng/ml) vs. femoral/jugular vein (2.1 ±0.4 ng/ml), /xO.0002; Iliac arteries (9.3±1.0 ng/ml) vs. iliac veins (4.8±0.9 ng/ml), /xO.005; aorta (14.0±1.6 ng/ml) vs. IVC ( 
T he antithrombotic and vasomotor properties of intact endothelium in vivo are dependent in part on endogenous biosynthesis and release of prostacyclin (PGI 2 ). This major product of arachidonic add metabolism in animal and human blood vessels is produced primarily by the endothelium, with its synthesis progressively decreasing (abluminal gradient) toward the adventitial surface. 1 -6 In conjunction with thromboxane, PGI 2 has a distinct role in platelet-vessel wall interaction, regulation of blood flow, and hemostatic and fibrinolytic response to injury and disease. 6 ' 7 ' 8 Additionally, its cytoprotective nature on a cellular, as well as a tissue, level has been described. 7 Endothelial biosynthesis of PGI 2 can be induced or blunted by various Interventions. Pharmacologic and chemical agents that stimulate its production include arachidonate, thrombin, calcium ionophore A23187, trypsin, dipyridamole, histamine, bradykinin, nitroglycerin, angiotensin II, high density lipoprotein, leukotriene C, interieukin-l, and interieukin-ll. 9 - 23 Conversely, PGI 2 formation can be suppressed or abolished by indomethacin, aspirin, tranylcypromine, 15-hydroperoxyarachidonic acid, linoleic acid, low density lipoprotein, glucocorticoids, calcium channel blockers, and cigarette smoke condensate. 59 - 24 - 31 Physiologic alterations, such as disordered blood flow, mechanical stress, high blood pressure, stasis, and low oxygen tension, or morphologic changes can result in enhanced vascular PGI 2 production. 12 -2832 - 38 Mechanical trauma and endothelial injury due to excision, ex vivo storage, and surgical preparation of vein segments before grafting may acutely impair the capacity of the venous endothelium to generate PG^, 3 9 4 0 4 1 while the chronic response to venoarterial grafting is increased production. 4243 Vessels vary in their ability to synthesize PGI 2 . Arterial endothelium produces significantly greater amounts than venous endothelium, 42 -45 a difference that may partially account for the higher patency rates of internal mammary artery compared to reversed saphenous vein grafts as coronary artery bypass conduits. 48 ' 47 Skidgel and Printz postulated a segmental variability of PGI 2 production in the same vessel; however, their study did not assess endogenous luminal production since it was based on addition of exogenous substrate prostaglandin H 2 (PGH 2 ) to vascular homogenates and rings. 38 To date, regional anatomic variability in arterial and venous endothelial PGI 2 biosynthesis from endogenous precursors has not been completely evaluated. Therefore, we investigated this regional variability in the unstimulated state to establish a baseline for further research on the regulation of PGI 2 biosynthesis.
Methods
Seventeen adult male and female mongrel dogs (weighing 18 to 35 kg) were studied. The animals were anesthetized with intravenous sodium pentobarbital (25 mg/kg), were endotracheally intubated, and were placed on controlled mechanical ventilation (Harvard Apparatus, Mills, MA). Through neck and bilateral groin incisions, we gently dissected and removed 1-cm segments of the carotid arteries, external jugular veins, femoral arteries, and femoral veins. A midline laparotomy was then performed followed by dissection and removal of 1-cm segments of abdominal aorta, inferior vena cava (IVC), iliac arteries, and iliac veins. Care was taken to avoid sampling vessels at branching points. The specimens were rinsed immediately with heparinized (1 lU/ml) saline at room temperature, were opened longitudinally, and were placed into a custom-designed incubation chamber apparatus described in previous reports. 44243 The apparatus exposed 36 mm 2 of the flow surface of the vessel for assay. The upper and lower plates were apposed to avoid leakage of the fluid from the chambers. A 300-jul aliquot of Tris-NaCI buffer (pH 8.6, 37°C) was placed into the incubation well for exactly 2 minutes, after which the fluid was pipetted into a polypropylene tube and frozen immediately at -70°C for subsequent analysis. All vessel specimens were treated in the same fashion with a maximum of 10 minutes elapsing from the time of vessel harvest to completion of sample freezing.
Vessel luminal PGI 2 production was measured in the basal state by radioimmunoassay for 6-keto-PGF 1a (6-ketoprostaglandin F 1a , the stable metabolite of PGI 2 ) in duplicate with the use of tritiated 6-keto-PGF 1a tracer and rabbit anti-6-keto-PGF lo antiserum (New England Nuclear, Boston, MA). Standard curves were constructed for each assay with known amounts of 6-keto-PGF,,, (500, 250, 100, 50, 25, and 10 pg/100 fi\). Values of 6-keto-PGF 1a are expressed as ng/ml of incubation fluid.
All animals received care in compliance with "Principles of Laboratory Animals Care" formulated by the National Society of Medical Research and the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Science and published by the National Institutes of Health (NIH publication 80-23, revised 1985) .
All continuous data are expressed as mean ±one standard error of the mean (SEM). The difference between the overall mean arterial and venous levels of 6-keto-PGF,,, and the differences between the mean 6-keto-PGF 1a in arteries and their anatomically corresponding veins were compared using Student's t test for unpaired data. Analysis of variance (ANOVA) was used to detect differences among the mean 6-keto-PGF 1o levels in each group (arterial or venous); if a significant difference was noted, Student's t test for unpaired data with the Bonferroni correction was performed. A two-tailed p value less than 0.05 (i.e., <0.017 adjusted for three multiple comparisons) was considered to be statistically significant.
Results
A total of 90 arterial and 41 venous segments were analyzed. Fifty-seven, 19, and 14 segments, respectively, of femoral/carotid artery, iliac artery, and aorta were studied. There were 15, 10, and 16 segments, respectively, of femoral/jugular vein, iliac vein, and IVC available for analysis. Overall, the mean arterial endothelial level of 6-keto-PGF 1a was significantly greater than the mean venous level (8.1 ±0.5 ng/ml vs. 4.9±0.7 ng/ml, p<0.0004). Accounting for the respective anatomic regions, the luminal levels of 6-keto-PGF 1o in the arteries were greater than those in their corresponding veins [femoral/carotid arteries (6.3±0.4 ng/ml) vs. femoral/jugular veins (2.1 ±0.4 ng/ml), p<0.0002; iliac arteries (9.3±1.0 ng/ml) vs. iliac veins (4.8±0.9 ng/ml), p<0.005; aorta (14.0±1.6 ng/ml) vs. IVC (7.5±1.4 ng/ml), p<0.006)] (Figure 1 ). Within the arterial group, the 6-keto-PGF 1a levels were significantly higher in the proximal, i.e., more centrally located vessels than those in the periphery (ANOVA, F=23.9, p=0.0001; femoral/carotid vs. iliac, p<0.0008; iliac vs. aorta, p<0.015; femoral/carotid vs. aorta, p<0.0002) (Figure 2 significantly higher levels in the proximal, or more centrally located, vessels compared to those in the periphery. All layers of the vascular wall are capable of synthesizing PGI 2 ; however, the intima produces a disproportionately high amount, generating about 40% of the total endogenous PGI 2 while representing only 5% of the arterial tissue. 3 Because PGI 2 formed by the deeper layers of the media normally does not reach the luminal surface, endothelial tissue is responsible for nearly all PGI 2 at this critical interface of platelet-vessel wall interaction. 4 The usual source of substrate for PGI 2 production appears to be intracellular pools of esterified fatty acid within the endothelium; upon synthesis, it is released immediately from the cells, so that synthesis is synonymous with release. 48 Skidgel and Printz 36 reported that rat arteries generated greater quantities of PGI 2 than did veins and further postulated a segmental distribution of PGI 2 synthetase activity in blood vessels. Because their study evaluated the utilization of an exogenous substrate PGH 2 by homogenates of vessels from various regions, it is possible that these observed regional differences reflected nonendothelial, as opposed to endothelial, PGI 2 production, since the contribution from the various layers could not be differentiated. In addition, tissue homogenization is traumatic and may affect utilization of exogenous precursors in PGI 2 synthesis, thereby possibly precluding an accurate assessment of prostaglandin metabolism in the normal state. Although intact vascular rings were also assessed by Skidgel and Printz, sampling was limited to the aorta and vena cava of only two rats, and the tissue was processed with the cut edges of the specimens (nonendothelial tissue) exposed during analysis; therefore, precise appreciation of baseline (i.e., unstimulated) endogenous endothelial PGI 2 production and its regional variability was not possible. In this study, we systemically evaluated specimens from various regions of the arterial and venous vasculature by using a specific radioimmunoassay for the stable hydrolysis product 6-keto-PGF 1o as described by Eldor et al., 4 and we confined the area of analysis to the luminal surface of these vessels to achieve a better understanding of the role of PGI 2 on the endothelial surface, i.e., the site of platelet-vessel wall interaction in the normal physiologic state.
Postulated explanations and mechanisms for higher PGI 2 production in arterial compared to venous tissue include a variety of mechanical and biochemical factors, such as greater hemodynamic stress associated with higher blood flow and pressure, differences in oxygen content and tension, increased endothelial turnover rate, and enzyme induction.
3234 -384249 - 52 It is known that PGI 2 production in vascular tissue 35 and endothelial cell cultures 5152 is increased by mechanical and pulsatile shear stress, with the dependence on shear rate being more marked in the presence of platelets. 50 Additionally, arteries from spontaneously hypertensive rats have an enhanced capacity (compared to normal tissue) to convert arachidonic acid to PG^, 33 presumably as a consequence of greater mechanical stress. To clarify the effects of blood pressure and flow on PGI 2 production, Eldor et al. 4 analyzed canine venous segments transplanted for 6 weeks into the arterial circulation and noted no significant difference in spontaneous and arachidonatestimulated PGI 2 synthesis between arterialized venous autografts and control veins. 44 Conversely, our group and others demonstrated that interposition of venous grafts into the arterial position in canine 4243 and rat 34 models for an extended period, for example, 10 to 12 weeks, resulted in increased graft luminal production of PGI 2 equalling the level of normal arteries. This finding is consistent with the concept that higher flows, pressures, and shear stress in the arterial circulation 3250 contribute to enhanced PGI 2 production. We subsequently noted that this timedependent biochemical "arterialization" was incomplete, since no significant response to substrate enhancement with arachidonic acid occurred in canine venoarterial autografts. 43 Interestingly, studies focused on the effects of aging on PGI 2 formation revealed no difference between young and mature porcine aortic intimal strips in the basal state, but in the presence of exogenous arachidonic acid, young intimal strips possessed a twofold greater ability to produce PGI 2 than did mature tissues. 53 Therefore, endothelial changes associated with arterialization and the decreased capacity for PGI 2 formation after substrate enhancement may be comparable to those associated with maturation or aging.
Venous endothelium is morphologically distinct from arterial endothelium, 54 but it is unknown whether this represents different cell types or structural (and/or biochemical) phenotypic modulation of endothelial cell function with concomitant activation of PGI 2 synthetic pathways as a result of increased blood flow. 55 The nature of this activation, which occurred during the "sprouting" phase of cultured endothelial cell growth, 55 has yet to be elucidated. But if this in vitro sprouting occurs in vivo, then it may represent a physiologic mechanism that lends a degree of protection from the deleterious effects of platelet aggregation and release. The adaptation of venoarterial graft endothelium, therefore, may reflect a normal chronic cellular response to the arterial environment, thereby inhibiting platelet adhesion and plateletendothelial interaction.
311
Oxygen tension and ischemia are possible regulators of PGI 2 synthesis. 373856 It has been speculated that exposure to higher oxygen content or tension in the arterial system may account for greater PGI 2 production in arteries compared to veins. 34 Experimental evidence, however, has been to the contrary. Venous stasis and ischemia have been shown to cause an initial increase in PGI 2 formation, 3756 with subsequent exhaustion of this effect after several similar interventions. 37 Studies in healthy subjects indicated an increase in urinary excretion of PGI 2 metabolites during heavy leg exercise without altering urinary excretion of thromboxane A 2 metabolites, implying that augmentation of PGI 2 production may be an independent process. 56 The excretion of PGI 2 metabolites increased more than sevenfold during the hour of exertion and decreased to pre-exercise level after 3 to 4 hours. 57 Exercise-induced alterations in blood pressure and cardiac output, both of which may contribute to the observed findings, however, were not assessed. In addition, the generation of 6-keto-PGF 1a was significantly higher when arterial tissue was subjected to a high nitrogen/low oxygen environment. 38 Thus, reduction in oxygen supply may be a trigger to increased PGI 2 production, but the influence of other concomitant metabolic alterations, such as changes in pH and accumulation of acidic metabolites, remains to be elucidated. 37 The proposed mechanisms-hemodynamic stress, blood flow, endothelial turnover, and enzyme inductionaccounting for differences in PGI 2 synthesis between the arterial and venous endothelium 32 -343642405051 may also be relevant in understanding the regional variability of PGI 2 production. Oxygen content and ischemia may possibly influence PGI 2 synthesis, but this effect was negligible in this study since they did not vary in the arterial or venous regions from which the segments were obtained. Investigating PGI 2 production at different sites of aortic wall in healthy rabbits and in rabbits with atherosclerosis, Voss et al. found that, contrary to previous studies, 5859 plaque-containing regions generated higher amounts of PGI 2 than did normal areas. 49 Because the areas with the most severe atherosclerotic changes were also assumed to be subject to the greatest hemodynamic stress along the aorta, 48 the balance of these two opposing factors on PGI 2 synthesis might result in the net increase observed. In normal animals, the highest PGI 2 -synthesizing capacity was found in the aortic arch and near the ostia of the major abdominal arteries 49 ; when regions surrounding the ostia were examined, there was a trend, though not statistically significant, toward greater PGI 2 formation in the distal as opposed to the proximal side. 60 In addition, endothelium in areas of artificial arterial stenosis (with resultant disordered blood fbw and turbulence) increased PGI 2 output that was stenosis-size dependent; that is, the greater the degree of stenosis, the greater the increase in its synthesis. 32 These findings may be the consequence of higher wall shear stress.
3260
In the normal arterial system, wall tension, mean arterial pressure, and mean flow velocity are higher in the aorta than in the peripheral large and medium-sized arteries. 6162 The endothelium is subjected to only a small fraction of the radial stress produced by blood pressure, which is borne mostly by elastic and collagen in the vessel wall; wall shear stress, however, is borne entirely by the endothelial layer. 63 Because mean flow velocity and transmission of energy from the flowing blood to the vessel wall are greater in the aorta compared to smaller arteries, the shear stress on the aortic endothelium is higher than that on endothelial cells of the peripheral arteries. In this study, the finding that endothelial PGI 2 production is significantly greater in the aorta than in iliac and femoral arteries may be the result of higher mean flow velocity and resultant shear stress.
Similar segmental physiologic differences exist in the venous vasculature. The wall tension, mean flow velocity, and shear stress are normally greater in the IVC than in smaller peripheral veins (including the iliac and femoral veins); mean blood pressure, however, is less in centrally located veins than in those in the periphery. 61 As in the arterial system, physiologic variations in mean flow velocity and shear stress may thus account for greater PGI 2 production by the IVC compared to the peripheral veins. Hence, regional variability-more centrally located vessels generating greater amounts of PGI 2 -may be due to regional hemodynamic differences.
Another endothelial biosynthetic product, which may be identical to nitric oxide, is endothelium-derived relaxing factor (EDRF). 646568 Although their mechanisms are different (e.g., PGI 2 acts via adenylate cyclase, whereas EDRF acts via guanylate cyclase), EDRF has features distinctly similar to PGI 2 , including a short half-life (6 seconds vs. 2 to 3 minutes for PGI 2 ) and potent vasodilator/ and antithrombotic properties. 76467 In addition, EDRF synthesis and release are stimulated by moderate hypoxia, a variety of pharmacologic agents, and increased flow. 788 Recently, it has been shown that EDRF production is greater in artery compared to vein in humans. 89 In view of the regional heterogeneity observed in our canine study, the question of whether EDRF production has a similar regional distribution must be investigated.
Some limitations of this study should be addressed. The intent of this investigation was to evaluate PGI 2 production in various segments of the arterial and venous vasculature in the normal unstimulated state. It can be hypothesized that this regional variability of basal PGI 2 is also present when the various segments are provided with enough substrate (e.g., arachidonic acid) enhancement; however, this question was not addressed in this experiment. Additionally, blood pressure, velocity, flow, and wall shear stress were not directly measured or calculated in the various regions of the vasculature from which the specimens were obtained; interpretations of the findings, therefore, are based on existing hemodynamic inferences.
In summary, arterial endothelial PGI 2 production is generally greater than that in venous endothelium; specifically, PGI 2 synthesis is greater in the arteries than in their anatomically corresponding veins. Within the arterial and venous systems, there exists regional variability in PGI 2 production with greater activity in the more centrally located vessels, possibly in response to greater mean flow velocity and shear stress. The findings in this study are of particular relevance to future investigations of PGI 2 biosynthesis in various regions of the vasculature.
